SBIR 主题 255，第二阶段：针对前列腺癌的合成疫苗-猫眼课题宝

SBIR 主题 255，第二阶段：针对前列腺癌的合成疫苗

批准号：

8351886

负责人：

PETER PUSHKO

金额：

$148.31万

依托单位：

MEDIGEN, INC.

依托单位国家：

美国

项目类别：

财政年份：

2011

资助国家：

美国

项目状态：

已结题

起止时间：

2011-09-29 至 2013-09-28

来源：

https://reporter.nih.gov/project-details/8351886

关键词：

Animal Model Antibody Formation Antigens Biological Assay CD8B1 gene Cancer Control Chemistry Collaborations Contracts Data Dendritic Cells Development Dose Engineering Evaluation Genes Goals Human Immunotherapy Malignant neoplasm of prostate Maryland Methods Mus Phase Preparation Procedures Process Production Prostate Cancer Vaccine Prostate-Specific Antigen Public Health Quality Control Regimen Research Route Safety Serum Small Business Innovation Research Grant Structure of base of prostate Synthetic Vaccines T-Lymphocyte Transgenic Mice United States Food and Drug Administration Universities Vaccinated Vaccination Vaccine Antigen Vaccine Production Vaccines Variant Virus-like particle assay development cancer immunotherapy design expression vector follow-up immunogenicity improved in vivo meetings novel novel therapeutics novel vaccines protective effect protective efficacy research study scale up therapeutic vaccine tumor vaccine candidate vaccine efficacy vector

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

This Phase II, SBIR contract is for the advanced vaccine efficacy studies, which involve TRAMP tumor challenge of vaccinated PSA+ transgenic mice. Engineered for increased immunogenicity PSA variants will be delivered and expressed in PSA+ mice using novel ¿vector VLP¿ (vVLP_ vaccine platform. The latter represent non-replicating virus-like particles configured to encapsidate expression vector for in vivo delivery and expression of engineered PSA genes.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文

海外基金

SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER

项目摘要

项目成果

相似基金

相关文献